SEARCH

SEARCH BY CITATION

References

  • 1
    KaserA, ZeissingS, BlumbergRS. Inflammatory Bowel disease. Annu Rev Immunol2010; 28: 573621.
  • 2
    Van DeventerSJ. Tumour necrosis factor and Crohn's disease. Gut1997; 40: 4438.
  • 3
    BreeseEJ, MichieCA, NichollsSW, et al.Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology1994; 106: 145566.
  • 4
    SchreiberS, NikolausS, HampeJ, et al.Tumour necrosis factor α and interleukin 1β in relapse of Crohn's disease. Lancet1999; 353: 45961.
  • 5
    TarganSR, HanauerSB, Van DeneverSJ, et al.A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med1997; 337: 102935.
  • 6
    HanauerSB, FeaganBG, LichtensteinGR, et al.Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet2002; 359: 15419.
  • 7
    SandsBE, AndersonFH, BernsteinCN, et al.Infliximab maintenance therapy for fistulizing Crohn's Disease. N Engl J Med2004; 350: 87685.
  • 8
    PresentDH, RutgeertsP, TarganS, et al.Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med1999; 340: 1398405.
  • 9
    RutgeertsP, DiamondRH, BalaM, et al.Scheduled maintenance treatment with Infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc2006; 63: 43317.
  • 10
    DignassA, Van AsscheG, LindsayJO, et al.The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: current management. J Crohns Colitis2010; 4: 2862.
  • 11
    BaertF, NomanM, VermeireS, et al.Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med2003; 348: 6018.
  • 12
    HanauerSB, SandbornWJ, RutgeertsP, et al.Human anti tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology2006; 130: 32333.
  • 13
    SandbornWJ, HanauerSB, RutgeertsP, et al.Adalimumab for maintenance treatment of Crohn's disease results of the CLASSIC II trial. Gut2007; 56: 12329.
  • 14
    ColombelJF, SandbornWJ, RutgeertsP, et al.Adalimumab is effective in maintenance of clinical response and remission in patients with active Crohn's disease: results of the CHARM trial. Gastroenterology2007; 132: 5265.
  • 15
    RutgeertsP, Van AsscheG, SandbornWJ, et al.Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology2012 [Epub ahead of print].
  • 16
    SandbornWJ, RutgeertsP, EnnsR, et al.Adalimumab induction therapy for Crohn's disease previously treated with infliximab: a randomized trial. Ann Intern Med2007; 146: 82938.
  • 17
    HinojosaJ, GomollónF, GarcíaS, et al.Efficacy and safety of short-therm adalimumab treatment in patients with active Crohn's disease who loss response or showed intolerance to infliximab: a prospective, open label, multicenter trial. Aliment Pharmacol Ther2007; 25: 40918.
  • 18
    Van AsscheG, DignassA, PanesJ, et al.The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. J Crohns Colitis2010; 4: 727.
  • 19
    OrlandoA, ArmuzziA, PapiC, et al.The Italian Society of Gastroenterology (SIGE) and the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) clinical practice guidelines: the use of tumor necrosis factor-alpha antagonist therapy in inflammatory bowel disease. Dig Liver Dis2011; 43: 120.
  • 20
    CottoneM, RosselliM, OrlandoA, et al.Smoking habits and recurrence in Crohn's disease. Gastroenterology1994; 106: 6438.
  • 21
    SilverbergMS, SatsangiJ, AhmadT, et al.Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol2005; 19: 536.
  • 22
    BestWR, BecktelJM, SingletonJW, et al.Development of a Crohn's disease activity index: National Cooperative Crohn's Disease Study. Gastroenterology1976; 70: 43944.
  • 23
    ClarkM, ColombelJF, FeaganBC, et al.American Gastroenterological Association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21–23, 2006. Gastroenterology2007; 133: 31239.
  • 24
    SchwartzDA, PembertonJH, SandbornWJ. Diagnosis and treatment of perianal fistulas in Crohn disease. Ann Intern Med2001; 135: 90618.
  • 25
    GuyattG, MitchellA, IrvineEJ, et al.A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology1989; 96: 80410.
  • 26
    SchnitzlerF, FidderH, FerranteM, et al.Long-term outcome of treatment with Infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut2009; 58: 492500.
  • 27
    HaC, UllmanTA, SiegelCA, et al.Patients enrolled in randomized controlled trials do not represent the inflammatory bowel disease patient population. Clin Gastroenterol Hepatol2012 [Epub ahead of print].
  • 28
    TrinderMW, LawranceIC. Efficacy of adalimumab for the management of inflammatory bowel disease in the clinical setting. J Gastroenterol Hepatol2009; 24: 12527.
  • 29
    CohenRD, KisielJB, HanauerSB. Infliximab in Crohn's disease: first anniversary clinical experience. Am J Gastroenterol1999; 94: A2642.
  • 30
    FarrellRJ, ShahSA, LodhaviaPJ, et al.Clinical experience with Infliximab therapy in 100 patients with Crohn's disease. Am J Gastroenterol2000; 95: 34907.
    Direct Link:
  • 31
    SwogerJM, LoftusEV, TremaineWJ, et al.Adalimumab for Crohn's disease in clinical practice at Mayo clinic: the first 118 patients. Inflamm Bowel Dis2010; 16: 191221.
  • 32
    SchreiberS, Khaliq-KareemiM, LauwranceI, et al.Mainteinance therapy with certulizumab pegol for Crohn's disease. N Engl J Med2007; 357: 23950.
  • 33
    KugathasanS, SaubermannL, SmithL, et al.Mucosal T-cell immunoregulation varies in early and late inflammatory bowel disease. Gut2007; 56: 1696705.
  • 34
    LouisE, BelaicheJ, ReenaersC. Anti-Tumor Necrosis factor nonresponders in Crohn's disease: therapeutic strategies. Dig Dis2009; 27: 3517.
  • 35
    VermeireS, LouisE, CarbonezA, et al.Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease. Am J Gastroenterol2002; 97: 235763.
    Direct Link:
  • 36
    SprakesMB, FordAC, WarrenL, et al.Efficacy, tolerability, and predictors of response to infliximab therapy for Crohn's disease: a large single centre experience. J Crohns Colitis2012; 6: 14353.
  • 37
    CheifetzA, SmedleyM, MartinS, et al.The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol2003; 98: 131524.
    Direct Link: